Pazopanib

5 - ( (4 - ( ( 2,3-dimethyl -2H- indazol- 6-yl) methylamino) -2-pyrimidinyl ) amino )-2- methylbenzenesulfonamide

L01XE11

Template: Infobox chemical / molecular formula search available

Pazopanib is a drug from the group of tyrosine kinase inhibitors. The orally active compound in 2010 was approved in the EU for the treatment of advanced and / or metastatic Nierenzellkarzioms.

Effect

The TKI uses the one hand, the tumor directly and suppresses the other hand, the formation of new blood vessels that feed the tumor. The effect occurs via inhibition of several protein kinases ( VEGFR, PDGFR, KIT). The plasma half -life is 30 hours, which is why the intake usually once daily, with an interval for meal takes place.

Contraindications

It should not be administered pazopanib in case of hypersensitivity and severe hepatic impairment.

Side effects

Common adverse effects are gastrointestinal disturbances ( anorexia, abdominal pain, diarrhea, nausea, vomiting, taste disturbances ), elevation of liver enzymes, hypertension, fatigue, and hair color changes. The liver enzyme disorders are obviously on earlier than expected, which is why the manufacturer recommends frequent and stricter monitoring of liver function.

Interactions

As a substrate of CYP3A4 pazopanib may interact with numerous other medicines.

Trade names

Pazopanib is available in the form of tablets under the name Votrient.